LYEL vs. ABUS, IMTX, TYRA, CRMD, SANA, RAPP, MNMD, CGEM, PHAR, and SEPN
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Arbutus Biopharma (ABUS), Immatics (IMTX), Tyra Biosciences (TYRA), CorMedix (CRMD), Sana Biotechnology (SANA), Rapport Therapeutics (RAPP), Mind Medicine (MindMed) (MNMD), Cullinan Therapeutics (CGEM), Pharming Group (PHAR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs.
Lyell Immunopharma (NASDAQ:LYEL) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.
Lyell Immunopharma has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.
Arbutus Biopharma has higher revenue and earnings than Lyell Immunopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma has a net margin of -1,137.65% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Arbutus Biopharma's return on equity.
Lyell Immunopharma presently has a consensus target price of $1.00, indicating a potential upside of 42.71%. Arbutus Biopharma has a consensus target price of $5.50, indicating a potential upside of 60.68%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Arbutus Biopharma is more favorable than Lyell Immunopharma.
Arbutus Biopharma received 421 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 71.08% of users gave Arbutus Biopharma an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.
66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Lyell Immunopharma had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Lyell Immunopharma and 1 mentions for Arbutus Biopharma. Lyell Immunopharma's average media sentiment score of 0.00 equaled Arbutus Biopharma'saverage media sentiment score.
Summary
Arbutus Biopharma beats Lyell Immunopharma on 10 of the 17 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free LYEL Stock Alerts